To overcome the limited access to patient-derived tumor cells and to directly detect the lipogenesis activity in patient-derived CSCs, organoids (PDOs) derived from patients with NSCLC were established, followed by analyses of CD133-expressing tumor cells. The gene discussed is PROM1; the disease is neoplasm.